How much revenue did Sprint Bioscience generate this year?
Sprint Bioscience has achieved a revenue of 98.98 M SEK this year.
In 2024, Sprint Bioscience's sales reached 98.98 M SEK, a 96.06% difference from the 50.49 M SEK sales recorded in the previous year.
YEAR | REVENUE (undefined SEK) | GROSS MARGIN (%) |
---|---|---|
2025e | 212.1 | 19,70 |
2024e | 98.98 | 42,22 |
2023 | 50.49 | 82,77 |
2022 | 0.08 | -15478,31 |
2021 | 35.11 | 70,28 |
2020 | 16.89 | 38,06 |
2019 | 33.54 | 75,63 |
2018 | 17.94 | 41,89 |
2017 | 23.97 | 87,53 |
2016 | 34.99 | 98,80 |
2015 | 7.73 | 102,69 |
2014 | - | - |
2013 | 2.37 | 244,30 |
2012 | 1.59 | 235,85 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Sprint Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sprint Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sprint Bioscience’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Sprint Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Sprint Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Sprint Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sprint Bioscience’s growth potential.
Date | Sprint Bioscience Revenue | Sprint Bioscience EBIT | Sprint Bioscience Net Income |
---|---|---|---|
2025e | 212.1 M undefined | 133.32 M undefined | 105.78 M undefined |
2024e | 98.98 M undefined | 20.2 M undefined | 21.16 M undefined |
2023 | 50.49 M undefined | -845,000 undefined | -438,000 undefined |
2022 | 83,000 undefined | -60.74 M undefined | -60.17 M undefined |
2021 | 35.11 M undefined | -25.63 M undefined | -25.08 M undefined |
2020 | 16.89 M undefined | -37.68 M undefined | -42.79 M undefined |
2019 | 33.54 M undefined | -20.43 M undefined | -21.54 M undefined |
2018 | 17.94 M undefined | -31.75 M undefined | -31.89 M undefined |
2017 | 23.97 M undefined | -10.67 M undefined | -10.66 M undefined |
2016 | 34.99 M undefined | 4.57 M undefined | 4.54 M undefined |
2015 | 7.73 M undefined | -15.36 M undefined | -15.5 M undefined |
2014 | 0 undefined | -11.26 M undefined | -11.46 M undefined |
2013 | 2.37 M undefined | -4.16 M undefined | -4.39 M undefined |
2012 | 1.59 M undefined | -5.24 M undefined | -3.55 M undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2012 | 1.59 M SEK | -5.24 M SEK | -3.55 M SEK |
2013 | 2.37 M SEK | -4.16 M SEK | -4.39 M SEK |
2014 | 0 SEK | -11.26 M SEK | -11.46 M SEK |
2015 | 7.73 M SEK | -15.36 M SEK | -15.5 M SEK |
2016 | 34.99 M SEK | 4.57 M SEK | 4.54 M SEK |
2017 | 23.97 M SEK | -10.67 M SEK | -10.66 M SEK |
2018 | 17.94 M SEK | -31.75 M SEK | -31.89 M SEK |
2019 | 33.54 M SEK | -20.43 M SEK | -21.54 M SEK |
2020 | 16.89 M SEK | -37.68 M SEK | -42.79 M SEK |
2021 | 35.11 M SEK | -25.63 M SEK | -25.08 M SEK |
2022 | 83,000 SEK | -60.74 M SEK | -60.17 M SEK |
2023 | 50.49 M SEK | -845,000 SEK | -438,000 SEK |
2024e | 98.98 M SEK | 20.2 M SEK | 21.16 M SEK |
2025e | 212.1 M SEK | 133.32 M SEK | 105.78 M SEK |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Sprint Bioscience's sales revenue. A higher gross margin percentage indicates that the Sprint Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Sprint Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Sprint Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sprint Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sprint Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sprint Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Sprint Bioscience Gross margin | Sprint Bioscience Profit margin | Sprint Bioscience EBIT margin | Sprint Bioscience Profit margin |
---|---|---|---|
2025e | 82.77 % | 62.86 % | 49.87 % |
2024e | 82.77 % | 20.41 % | 21.37 % |
2023 | 82.77 % | -1.67 % | -0.87 % |
2022 | -15,478.31 % | -73,180.72 % | -72,493.98 % |
2021 | 70.28 % | -72.99 % | -71.43 % |
2020 | 38.06 % | -223.13 % | -253.43 % |
2019 | 75.63 % | -60.92 % | -64.21 % |
2018 | 41.89 % | -177.03 % | -177.82 % |
2017 | 87.53 % | -44.51 % | -44.49 % |
2016 | 98.8 % | 13.05 % | 12.98 % |
2015 | 102.69 % | -198.75 % | -200.61 % |
2014 | 82.77 % | 0 % | 0 % |
2013 | 244.3 % | -175.53 % | -185.23 % |
2012 | 235.85 % | -329.56 % | -223.27 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2012 | 235.85 % | -329.56 % | -223.27 % |
2013 | 244.3 % | -175.53 % | -185.23 % |
2014 | 82.77 % | 0 % | 0 % |
2015 | 102.69 % | -198.75 % | -200.61 % |
2016 | 98.8 % | 13.05 % | 12.98 % |
2017 | 87.53 % | -44.51 % | -44.49 % |
2018 | 41.89 % | -177.03 % | -177.82 % |
2019 | 75.63 % | -60.92 % | -64.21 % |
2020 | 38.06 % | -223.13 % | -253.43 % |
2021 | 70.28 % | -72.99 % | -71.43 % |
2022 | -15,478.31 % | -73,180.72 % | -72,493.98 % |
2023 | 82.77 % | -1.67 % | -0.87 % |
2024e | 82.77 % | 20.41 % | 21.37 % |
2025e | 82.77 % | 62.86 % | 49.87 % |
The sales figures of Sprint Bioscience originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Analyzing Sprint Bioscience’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Investors often scrutinize Sprint Bioscience's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Increases in Sprint Bioscience’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Sprint Bioscience has achieved a revenue of 98.98 M SEK this year.
The revenue of Sprint Bioscience has increased by 96.06% increased compared to the previous year.
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
The revenue of Sprint Bioscience is influenced by various factors, including the demand for its products and services, market conditions, and prices.
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
The revenue of Sprint Bioscience is an important indicator of financial performance and attractiveness for investors.
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.
The current dividend yield of Sprint Bioscience is .
Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .
Sprint Bioscience paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
Sprint Bioscience is assigned to the 'Health' sector.
To receive the latest dividend of Sprint Bioscience from 7/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.
The last dividend was paid out on 7/22/2024.
In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.
The dividends of Sprint Bioscience are distributed in SEK.
Our stock analysis for Sprint Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sprint Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.